These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 27119231)

  • 1. Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1.
    Voena C; Varesio LM; Zhang L; Menotti M; Poggio T; Panizza E; Wang Q; Minero VG; Fagoonee S; Compagno M; Altruda F; Monti S; Chiarle R
    Oncotarget; 2016 May; 7(22):33316-30. PubMed ID: 27119231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.
    Kogita A; Togashi Y; Hayashi H; Sogabe S; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
    Int J Oncol; 2014 Oct; 45(4):1430-6. PubMed ID: 25096400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
    Wu F; Li J; Jang C; Wang J; Xiong J
    Int J Clin Exp Pathol; 2014; 7(10):6653-61. PubMed ID: 25400744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
    Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
    Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
    Pailler E; Adam J; Barthélémy A; Oulhen M; Auger N; Valent A; Borget I; Planchard D; Taylor M; André F; Soria JC; Vielh P; Besse B; Farace F
    J Clin Oncol; 2013 Jun; 31(18):2273-81. PubMed ID: 23669222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
    Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.
    Alidousty C; Baar T; Martelotto LG; Heydt C; Wagener S; Fassunke J; Duerbaum N; Scheel AH; Frank S; Holz B; Binot E; Kron A; Merkelbach-Bruse S; Ihle MA; Wolf J; Buettner R; Schultheis AM
    J Pathol; 2018 Sep; 246(1):67-76. PubMed ID: 29885057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib].
    Lin CC; Lu CH; Pan YH; Jiao L; Chen HY; Li L; He Y
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):650-656. PubMed ID: 28926892
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
    Bayliss R; Choi J; Fennell DA; Fry AM; Richards MW
    Cell Mol Life Sci; 2016 Mar; 73(6):1209-24. PubMed ID: 26755435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of histamine H4 receptors decreases epithelial-to-mesenchymal transition progress by inhibiting transforming growth factor-β1 signalling pathway in non-small cell lung cancer.
    Cai WK; Hu J; Li T; Meng JR; Ma X; Yin SJ; Zhao CH; He GH; Xu GL
    Eur J Cancer; 2014 Apr; 50(6):1195-206. PubMed ID: 24447834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome Inhibition Overcomes ALK-TKI Resistance in
    Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
    Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.
    Saraceni C; Li PM; Gainor JF; Stopyra GA; Friedman EL
    J Thorac Oncol; 2015 Jul; 10(7):1116-7. PubMed ID: 26134230
    [No Abstract]   [Full Text] [Related]  

  • 17. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
    Weng CH; Chen LY; Lin YC; Shih JY; Lin YC; Tseng RY; Chiu AC; Yeh YH; Liu C; Lin YT; Fang JM; Chen CC
    Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.
    Tiseo M; Gelsomino F; Bartolotti M; Bordi P; Bersanelli M; Rossi G; Ardizzoni A
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1677-87. PubMed ID: 22050016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.